AAM Proposes HHS Directly Incentivize Drug Makers To Spur U.S. Base

By Beth Wang / April 30, 2020 at 2:19 PM
The generic drug lobby is floating a policy proposal to secure the pharmaceutical supply chain under which HHS would identify essential U.S. medicines and then proactively incentivize both individual companies and the entire industry to ramp up domestic manufacturing, including through streamlined FDA regulations, tax incentives, and long-term price and volume guaranteed contracts. The Association for Accessible Medicines says its proposed policy framework, released Thursday (April 30), would help reduce U.S. reliance on foreign drug manufacturing, a problem highlighted by...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.